Table of Contents
- Clinical trials at a glance
- Conditions being studied
- Trial phases and study designs
- Main endpoints being measured
- Who may take part
- Notable study comparisons
- What these trials mean for patients
Clinical trials at a glance
Clinical trials are testing Zanubrutinib in a wide range of diseases, mostly B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia.[1] Some trials also study non-cancer conditions, including primary membranous nephropathy, cold agglutinin disease, and anti-MAG neuropathy.[2]
The studies include people who are newly diagnosed, people whose disease has come back, and people whose disease did not respond to earlier treatment.[3] Many trials compare Zanubrutinib with another treatment, and many also test it in combination with other medicines.[4]
Conditions being studied
Several trials focus on chronic lymphocytic leukemia, also called CLL, and small lymphocytic lymphoma, or SLL.[5] These include studies in previously untreated patients and in relapsed or refractory disease, which means the disease came back or did not respond well to prior treatment.[6]
Other studies focus on mantle cell lymphoma, follicular lymphoma, splenic marginal zone lymphoma, marginal zone lymphoma, and Richter transformation.[7] There are also trials in Waldenström’s macroglobulinemia, cold agglutinin disease, and peripheral anti-MAG neuropathy, which is a nerve problem linked to certain antibodies.[8]
One Phase 4 study looks at primary membranous nephropathy, a kidney disease where the trial measures urine protein loss and complete remission.[2]
Trial phases and study designs
The Zanubrutinib program includes Phase 1, Phase 2, Phase 3, and Phase 4 studies.[9] Phase 1 trials mainly focus on safety, side effects, and dose questions, while Phase 2 and Phase 3 trials look more closely at how well the treatment works.[10] Phase 4 studies follow treatment in larger or later settings and may compare Zanubrutinib with another standard treatment.[11]
Some studies are open-label, which means both the researchers and the participants know which treatment is being given.[1] Other studies are randomized, meaning people are assigned by chance to different treatment groups.[7]
Combination studies are common. Zanubrutinib is being studied with medicines such as obinutuzumab, rituximab, venetoclax, sonrotoclax, tislelizumab, glofitamab, mosunetuzumab, and emavusertib in different diseases.[12]
Main endpoints being measured
The most common endpoint is progression-free survival, or PFS, which means the time before the disease gets worse or the person dies from any cause.[4] Many studies use PFS because it shows whether a treatment can delay disease growth for a meaningful time.[7]
Other studies measure overall response rate, which counts how many people have a complete or partial response.[1] Several trials also measure complete response, complete response with incomplete bone marrow recovery (CRi), or minimal residual disease (MRD), which means very small amounts of disease that may remain after treatment.[12]
Some non-cancer studies use different outcomes. For example, the neuropathy studies measure improvement in disability or neurological scores, and the kidney study measures urine protein creatinine ratio and complete remission.[3] Safety is also a key endpoint in some trials, including studies that count treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities.[9]
Who may take part
Each trial has its own entry rules, but the source data show several main groups of participants.[13] Some studies include adults with newly diagnosed disease, while others include people whose disease is relapsed or refractory.[10]
Several trials are limited to high-risk patients or patients with a specific disease stage, such as Richter transformation or mantle cell lymphoma in people who are not eligible for stem cell transplantation.[14] Other studies focus on people with special clinical features, such as young CLL patients with an adverse biologic profile or patients with anti-MAG neuropathy linked to IgM MGUS.[8]
Notable study comparisons
Some of the largest studies compare Zanubrutinib-based treatment with standard regimens. In previously untreated CLL, Zanubrutinib is compared with bendamustine plus rituximab, and in another study it is compared with venetoclax plus obinutuzumab.[5]
In relapsed or refractory lymphoma, Zanubrutinib is compared with lenalidomide plus rituximab, or with obinutuzumab alone in follicular lymphoma.[7] In primary membranous nephropathy, it is compared with tacrolimus, and in splenic marginal zone lymphoma it is added to rituximab and compared with rituximab alone.[2]
Some studies test whether adding Zanubrutinib improves results when combined with newer medicines. These include combinations with sonrotoclax, tislelizumab, glofitamab, mosunetuzumab, and emavusertib.[4]
What these trials mean for patients
These trials are trying to learn which patients may benefit most from Zanubrutinib and which combinations may work better than older treatment options.[1] The research is also looking at how deeply the disease can be controlled, including whether tests can no longer find measurable disease after treatment.[12]
Because the studies cover many diseases and phases, the results may help answer different questions: safety in early testing, response in small studies, and longer-term outcomes in larger comparison trials.[11] The trial data show that Zanubrutinib is being studied both alone and as part of multi-drug treatment plans across blood cancers and a few non-cancer conditions.[3]
